Xenon Pharmaceuticals Inc. XENE

XENE Company Overview

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for neurological disorders. The company primarily operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on precision medicines targeting ion channel dysfunction and other genetically validated neurological pathways. Xenon’s core revenue and value drivers are tied to its drug development pipeline, licensing collaborations, and intellectual property portfolio centered on epilepsy, depression, and other neurological conditions.

The company’s lead development programs include azetukalner (XEN1101), a potassium channel modulator being evaluated for epilepsy and major depressive disorder, and NBI-921352, formerly partnered with Neurocrine Biosciences for epilepsy-related indications. Xenon was founded in 1996 in Canada and initially focused on human genetics-driven drug discovery. Over time, the company shifted from broader genetics research toward a concentrated neurology-focused development strategy, particularly in rare and common epileptic disorders. Its positioning is strengthened by proprietary ion channel expertise, clinical-stage assets with differentiated mechanisms, and long-standing capabilities in translational genetics.